Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations

Journal of Bone and Mineral Research

Volumn 15, Issue 1, 2000, Pages 147-154

  Pecherstorfer, Martin ^a,c   Jilch, Ruth ^a   Sauty, Alain ^b   Horn, Eva ^a   Keck, Andrea Vera ^a   Zimmer Roth, Ilse ^a   Thiebaud, Daniel ^b  

^a GENERAL HOSPITAL LINZ   (Austria)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c WILHELMINEN HOSPITAL   (Austria)

Author keywords

Aminobisphosphonates; Bisphosphonates; Lymphocytes; Malignancy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ARTICLE; BODY TEMPERATURE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HELPER CELL; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL;

EID: 0033981553     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2000.15.1.147     Document Type: Article

References (34)

1. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AE, Gobelet C 1994 Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis 4:76-83.
2. Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA 1996 Comparison of three different intravenous regimens of clodronate in Paget's disease of bone. J Bone Miner Res 11:178-182.
3. Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ, for the Early Postmenopausal Intervention Cohort Study Group 1998 Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485-492.
4. Berenson JB, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493.
5. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiébaud D 1996 Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268-276.
6. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ 1996 Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous injection. J Bone Miner Res 11:587-593.
7. Fleisch H 1997 Bisphosphonates in Bone Disease: From Laboratory to Patient, 3rd Ed. Parthenon Publishing Group, New York. NY, U.S.A.
8. Brown RJ, Van Beek E, Watts DJ, Löwik CWGM, Papapoulos SE 1998 Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J Bone Miner Res 13:253-258.
9. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM 1987 Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301-1305.
10. Papapoulos SE 1995 Pharmacodynamics of bisphosphonates in man: Implications for treatment. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (eds.) Bisphosphonate on Bones. Elsevier Science B.V., Amsterdam, the Netherlands, pp. 231-245.
11. Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P 1997 An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386-392.
12. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burkhardt P, Thiéhaud D 1996 Interleukin-6 and tumor necrosis factor-alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 18:133-139.
13. Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thürlimann B, Walls J, Lichnitser MR, Rizzoli R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ 1997 Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 75:295-300.
14. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH 1997 Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307.
15. Restifo NP, Wunderlich JR 1997 Essentials of immunology. In: DeVita VT, Hellmann S, Rosenberg SA (eds.) Cancer. Principles and Practice of Oncology. 5th Ed, Vol 1. Lippincott-Raven, Philadelphia, PA, U.S.A., pp. 47-75.
16. Maino VC, Suni MA, Ruitenberg JJ 1994 Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry 20:127-133.
17. Ulich TR, del Castillo J, Keys M, Granger GA, Ni RX 1987 Kinetics and mechanisms of recombinant interleukin-1 and tumor necrosis factor alpha induced changes in circulating numbers of neutrophils and lymphocytes. J lmmunol 139:3406-3415.
18. Ulich TR, Shin SS, del Castillo J 1993 Hematologic effects of TNF. Res Immunol 144:347-354.
19. Ulich TR, del Castillo J, Ni RX, Bikhazi N, Calvin L 1989 Mechanism of tumor necrosis factor-alpha-induced lymphopenia, neutropenia, and biphasic neutrophilia: A study of lymphocyte recirculation and hematologic interaction of TNF-α with endogenous mediators of leukocyte trafficking. J Leuk Biol 45:155-167.
20. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA 1987 Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 84:9238-9242.
21. Cartwright JE, Whitley GS, Johnstone AP 1995 The expression and release of adhesion molecules by human endothelial cell lines and their consequent binding of lymphocytes. Exp Cell Res 217:329-335.
22. Sansoni P, Passeri G, Fagoni F, Mohagheghpour N, Snelli G, Brianti V, Engleman EG 1995 Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 10: 1719-1725.
23. Santis AG, Campanero MR, Alonso JL, Sánchez-Madrid FS 1992 Regulation of tumor-necrosis factor (TNF)-α synthesis and TNF receptor expression in T lymphocytes through the CD2 activation pathway. Eur J Immunol 22: 3155-3160.
24. Testi R, D'Ambrosio D, De Maria R, Santoni A 1994 The CD69 receptor: A multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 15: 479-483.
25. Ziegler SF, Ramsdell F, Alderson MR 1994 The activation antigen CD69. Stem Cells 12:456-465.
26. Lanier LL, Buck DW, Ding A, Evans E, Barney C, Phillips JH 1988 Interleukin2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J Exp Med 167:1572-1585.
27. Yokoyama WM, Koning F, Kehn PJ, Pereira GM, Stingl G, Coligan JE, Shevach EM 1988 Characterization of a cell surface-expressed disulfide-linked dimer involved in murine T cell activation. J Immunol 141:369-376.
28. Testi R, Phillips JH, Lanier LL 1989 Leu-23 induction as an early marker of functional CD3/T cell antigen receptor triggering. J Immunol 142:1854-1860
29. Dhabhar FS, Miller AH, Stein M, McEwen BS, Spencer RL 1994 Diurnal and acute stress-induced changes in distribution of peripheral blood leukocyte subpopulations. Brain Behav Immun 8:66-79.
30. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Cascio VL 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331.
31. Fitton A, McTavish D 1991 Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289-318.
32. O'Doherty DP, McCloskey EV, Vasikaran S, Khan S, Kanis JA 1995 The effects of intravenous alendronate in Paget's disease of bone. J Bone Miner Res 10:1094-1100.
33. Schweitzer DH, Oostendorp-van der Ruit M, van der Pluijm G, Löwik CWGM, Papapoulos SE 1995 Interleukin-6 and the acute phase response during treatment of Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956-962.
34. Ebetino FH, Dansereau SM 1995 Bisphosphonates' antiresorptive structure-activity relationships. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (eds.) Bisphosphonate on Bones. Elsevier Science B.V., Amsterdam, the Netherlands, pp. 140-153.